ObsEva SA (OBSV) is one of the leading innovative biopharmaceutical company engaged in the development and commercialization of innovative treatments to improve women’s reproductive health and pregnancy. The company mostly focuses on the cure of uterine fibroids, endometriosis, and preterm labor. One of the main candidate products of the company is Linzagolix associated with the treatment of pain in pre-menopausal women. Another lead product is Ebopiprant used for the treatment of preterm labor.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
The price of OBSV stock during the regular trading on January 3, 2022, was last checked to be $2.08 with a leap of 4.27%.
OBSV: Events and Happenings
On January 3, 2022, OBSV reported that the company’s executives will present the company and give corporate update at the approaching H.C. Wainwright BioConnect Conference, which will be held January 10-13, 2022. On December 20, 2021, OBSV reported about its addition to the NASDAQ Biotechnology Index with effect from December 20, 2021.
OBSV: CEO Comments
Brian O’Callaghan, CEO of the company on this occasion said that being a part of NASDAQ Biotechnology Index enabled the company to reach new customers and the company continued to grow and build its mark in the field of women reproductive health.
On December 17, 2021, OBSV reported that the Committee for Medicinal Products for Human Use of the European Medicines Agency had given encouraging opinion regarding the recommendation of the approval of linzagolix. It is in Phase 3 clinical trials. If approved, it would be a pioneer GnRH receptor adversary along with a non-hormonal selection choice.
On December 10, 2021, OBSV reported that the company’s executive management presented clinical development regarding linzagolix at the 7th Virtual Society of Endometriosis and Uterine Disorders Congress held on December 9-11, 2021. On November 22, 2021, OBSV reported that FDA had accepted its New Drug Application for linzagolix for review.
OBSV: Key Financials
On November 4, 2021, OBSV reported about its financial results for the quarter ended September 30, 2021. Some of the key updates are as follows
Net Income/Loss per Share
Basic and diluted net income for third quarter 2021 was $0.8 million, or $0.01 per share, against a net loss of $24.4 million, or $0.49 per share, for the same period of 2020.
Total Current Assets
Total current assets reported by the company for Q3 2021 were $72 million as compared to the same period of prior year when it was $56.2 million.
OBSV stock declined 27% as compared to the past six months. The current increase in the regular trading is possibly the product of the company’s latest announcement of attending Bioconnect conference. The conference will connect the company with the possible investors and stockholders of the company thus paving a way for its fruitful entry into the new year.